Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SCP2 | P22307 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 4/20 | 0.38 |
| ▸ | CASP1 | P29466 | 3/20 | 0.38 |
| ▸ | CASP7 | P55210 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23733292 | 0.96 | MEN1 (0.58) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL4664437 | 0.88 | MEN1 (0.76) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL18070239 | 0.88 | MEN1 (0.62) | MEN1KMT2APOLBNPC1RAB9A | |
| Nile Blue SCHEMBL12393690 | 0.86 | MEN1 (0.77) | MEN1KMT2APOLBNPC1RAB9A | |
| Nile Blue SCHEMBL29356294 | 0.86 | MEN1 (0.77) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL56792 | 0.86 | MEN1 (0.76) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL12393695 | 0.84 | MEN1 (0.59) | MEN1KMT2APOLBNPC1RAB9A | |
| Nile Blue SCHEMBL4051129 | 0.83 | MEN1 (0.71) | MEN1KMT2APOLBNPC1RAB9A | |
| Nile Blue SCHEMBL4051132 | 0.83 | MEN1 (0.71) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL18070331 | 0.82 | SCP2 (0.65) | MEN1KMT2APOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387631-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-11077210-B2 | Near-infrared fluorescent contrast bioimaging agents and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2021-08-03 | — | — | US | disclosed |
| US-11001562-B2 | Near-infrared fluorescent nerve contrast agents and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2021-05-11 | — | — | US | disclosed |
| US-20160347727-A1 | NEAR-INFRARED FLUORESCENT NERVE CONTRAST AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160263249-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263249-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015066296-A9 | NEAR-INFRARED FLUORESCENT NERVE CONTRAST AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015066296-A1 | NEAR-INFRARED FLUORESCENT NERVE CONTRAST AGENTS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347727-A1 | NEAR-INFRARED FLUORESCENT NERVE CONTRAST AGENTS AND METHODS OF USE THEREOF | INA, NTRK1, NGF | MEN1 676/4885KMT2A 4524/4885POLB 3835/4885 |
| US-11077210-B2 | Near-infrared fluorescent contrast bioimaging agents and methods of use thereof | CD68, MSR1, CD47 | MEN1 498/4885KMT2A 4412/4885POLB 3422/4885 |
| US-20220387631-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | CD68, MSR1, CD47 | MEN1 498/4885KMT2A 4412/4885POLB 3422/4885 |
| US-20160263249-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | CD68, MSR1, CD47 | MEN1 498/4885KMT2A 4412/4885POLB 3422/4885 |
| US-11001562-B2 | Near-infrared fluorescent nerve contrast agents and methods of use thereof | INA, NTRK1, NGF | MEN1 676/4885KMT2A 4524/4885POLB 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.